MolMed: Contact Details and Business Profile
Molmed, l'Opa giapponese in bilico per golden power - ilGiornale.it
MolMed: AIFA approva commercializzazione Zalmoxis. Titolo vola in Borsa - Economia e Finanza - Repubblica.it
European Population Genetic Substructure: Further Definition of Ancestry Informative Markers for Distinguishing among Diverse European Ethnic Groups | Molecular Medicine | Full Text
COMUNICATO STAMPA
Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer - ScienceDirect
MolMed now part of AGC Biologics | LinkedIn
European Population Genetic Substructure: Further Definition of Ancestry Informative Markers for Distinguishing among Diverse European Ethnic Groups | Molecular Medicine | Full Text
Molmed, la giapponese Agc supera il 50% in Opa - Il Sole 24 ORE
Antioxidants | Free Full-Text | Cellular Aging Characteristics and Their Association with Age-Related Disorders
Will MolMed soon have its first Cell therapy on the Market?
Il 2019 è l'anno della svolta per MolMed - MilanoFinanza.it
Azioni MolMed: Quotazione, Andamento e Previsioni | Emanuele Perini
Press release issued by MolMed S.p.A. at the request of AGC Inc. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PA
European Population Genetic Substructure: Further Definition of Ancestry Informative Markers for Distinguishing among Diverse European Ethnic Groups | Molecular Medicine | Full Text
Ultime Notizie Molmed News
MOLMED S.P.A. : MLM Stock Price | IT0001080248 | MarketScreener
MolMed - YouTube
Will MolMed soon have its first Cell therapy on the Market?
MolMed receives IND clearance by the FDA to conduct a Phase III trial of TK for high-risk leukaemia in the United States
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY IN, INTO OR FROM ANY JURISDICTION WHER
Sergio Signore (@signore_sergio) / Twitter
Will MolMed soon have its first Cell therapy on the Market?
